
    
      This Study is To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule Combined
      with Allitinib Tablets in First-line Treatment of Advanced No-squamous and No-small Cell Lung
      Cancer with Epidermal Growth Factor Receptor Mutation.

      This study is a single arm, phase II study, including 18 to 36 subjects; Common Terminology
      Criteria for Adverse Events 5.0 standard was used to evaluate adverse events of drugs, and
      Response Evaluation Criteria In Solid Tumors 1.1 was used to evaluated efficacy.
    
  